Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has extended the review timeline for the biologic license application for Centocor's ustekinumab, a subcutaneous biologic therapy, by three months to December 2008.
Subscribe to our email newsletter
The application, filed by Centocor late in 2007, seeks approval to market ustekinumab for the treatment of adult patients with chronic moderate to severe plaque psoriasis.
The FDA extended the review period to provide additional time for review of amendments to the application provided by Centocor within the last three months. The FDA has requested no additional clinical trials. Ustekinumab is also under review by the European Medicines Agency.